Combination treatment with a b-lactam plus a macrolide may improve the outcome for elderly patients with community-acquired pneumonia (CAP). The prognoses and mortality rates for elderly patients with CAP who receive ceftriaxone combined with a 3-day course of azithromycin or a 10-day course of clarithromycin were compared in an open-label, prospective study. Of 896 assessable patients, 220 received clarithromycin and 383 received azithromycin. There were no significant differences between groups with regard to the severity score defined by the Pneumonia Patient Outcomes Research Team (PORT) study group; the incidence of bacteremia was also not significantly different. However, for patients treated with azithromycin, the length of hospital stay was shorter ( , vs. days; ) and the mortality rate was lower (3.6% vs. mean ‫ע‬ SD 7.4 ‫ע‬ 5 ‫ע4.9‬ 7 P ! .01 7.2%; ), compared with those treated with clarithromycin. There might be a difference in the outcome P ! .05 for patients with CAP depending on the macrolide used. A shorter treatment course with azithromycin may result in better compliance with therapy.
Community-acquired pneumonia (CAP) is the most common infectious disease to cause hospitalization and related mortality, especially among elderly people in developed countries [1] . In some medical publications [2, 3] , it has been reported that the outcome for elderly patients (age, 165 years) with CAP may improve when a macrolide is combined with a second-or thirdgeneration cephalosporin. The success of the macrolide might be due to a high frequency of atypical pathogens causing mixed pneumonias [4, 5] , but an intrinsically anti-inflammatory effect of those antimicrobial agents could also be the cause [6, 7] . A beneficial effect was observed when patients with pulmonary diseases causing chronic inflammation, such as chronic obstructive pulmonary disease, panbronchiolitis, and bronchiectasis, were treated with macrolides [8] .
treated with ceftriaxone plus azithromycin or with clarithromycin. The LOS was calculated for those patients who required hospitalization. The exclusion criteria were as follows: ingestion difficulties, prior receipt of antibiotic therapy against CAP for у3 days, discharge from the hospital or death on day 1 of admission, and acute respiratory failure requiring mechanical ventilation.
Definition of terms. Patients were considered to have CAP if a new and persistent infiltrate was seen on the chest radiograph and if у3 of the other 5 standard American Thoracic Society criteria were present [11] : (1) typical clinical findings, (2) leukocytosis (leukocyte count, 110,000 cells/mL) or leukopenia (leukocyte count, !4000 cells/mL), (3) purulent sputum (120 granulocytes per low-power field), (4) fever (temperature, 138ЊC), and (5) isolation of a typical pneumonia pathogen.
Clinical status or comorbidity referred to diseases or therapies that could predispose patients to infection, alter defense mechanisms, or cause functional impairment. Laboratory findings at admission to the hospital were evaluated and scored to assess severity by using the prediction rule from the Observational Pneumonia Patient Outcomes Research Team (PORT) cohort study [12] . The severity of CAP was separated in 5 different categories or risk groups on the basis of the main variables identified in step 1 of the PORT rule developed by Fine et al. [13] . Patients with bacteremia were identified to assess whether the distribution of positive blood culture results was balanced in both treatment groups.
Follow-up. All patients were initially attended and evaluated in the emergency department, where they routinely stayed no longer than 24 h. Patients were admitted or discharged on the basis of their physical conditions, radiograph findings, and preliminary results of laboratory tests [13] . Patients were observed from the time of diagnosis of CAP until the convalescence controls were completed (4-6 weeks after discharge) or until in-hospital or CAP-related death occurred. Death was considered to be related to CAP if it occurred before the resolution of symptoms or signs or within the convalescence period, if there was no other explanation.
Study design.
The study was open-label, prospective, and nonrandomized. Beginning in January 1997, all patients aged у18 years who had CAP diagnosed in the emergency department of our 900-bed tertiary care, university-affiliated center are subjected to a standard study protocol and prospectively surveyed. According to this protocol, patients receive sequential intravenous ceftriaxone and oral amoxicillin-clavulanate, with or without a macrolide. Patients with CAP for whom a macrolide was indicated might receive clarithromycin or azithromycin, at the discretion of the attending physician. Empirically antipseudomonal treatment (cefepime-amikacin or levofloxacin) was initiated for patients who had received a у3-day course of whichever therapy was presumably active against the common respiratory flora. Patients received treatment courses for 10-14 days.
The antibiotic administration procedure, in either the clarithromycin or azithromycin group, was 1000 mg of ceftriaxone (after a starting dose of 2000 mg) in 50 mL of 0.9% saline as an intravenous infusion over 15 min once per day. After a minimum of 72 h, patients could be switched from intravenous to oral forms of therapy if they had demonstrated clinical improvement. After the switch to orally administered therapy, amoxicillin-clavulanate (875/125 mg) was administered 3 times per day. Clarithromycin was supplied as 500 mg of sterile powder for reconstitution in 10 mL of sterile water and was infused in 250 mL of suitable diluent over 60 min twice per day. Oral clarithromycin was administered as a 500-mg tablet twice per day for у10 days. Azithromycin was supplied as a 500-mg tablet once per day and was administered for 3 days. Oral therapies were surveyed during hospitalization but were self-administered after discharge.
Microbiological methods. A pair of blood samples were obtained for culture immediately before commencement of antimicrobial therapy from both febrile and nonfebrile patients. Samples of sputum and pleural fluid were routinely obtained when the patient expectorated or when radiography revealed accessible pleural effusion, respectively. Two blood samples were obtained for serological testing in parallel at admission to the hospital and within the fourth to the sixth week of follow-up. Etiology was established by blood cultures or representative respiratory specimen cultures, serological tests, and urinary antigen tests positive for Legionella pneumophila serogroup 1. During the 2 years of the study, blood cultures and pleural fluid specimens were processed by an automatic nonradiometric system. Invasive respiratory samples were always processed to discover conventional, opportunistic, and Legionella infections. Sputum samples were processed by a procedure established by Murray and Washington [14] . Therefore, only Gramstained samples with !10 epithelial cells per high-power field (G4 and G5) were cultured. Isolates were identified in accordance with standard techniques. Microbiological susceptibility was assessed by determining the MIC (by the microdilution method), in accordance with NCCLS methodology [15] .
Statistical analysis. Categorical variables were compared using the x 2 test or Fisher's exact test, when necessary; continuous variables were compared using Student's t test. Logistic regression analysis was performed to assess the independent association between clarithromycin or azithromycin treatment and the outcome variables (LOS and mortality) after controlling for potential confounding variables (age, sex, or presence of bacteremia). LOS was dichotomized by a cutoff of 7 days because that was the median value for all patients. All calculations were performed with the 2D and LR programs of the BMDP statistical package, release 7.0 (BMDP/DYNAMIC). 
RESULTS
During the study period, 1278 patients were treated for CAP in the emergency department. A total of 382 patients (30%) who were not considered to have severe pneumonia (Fine risk classes 1 and 2) were discharged from the emergency department and were treated as outpatients; none of them required later admission to the hospital for aggravation of CAP or therapy failure. A total of 896 patients (70%) were admitted to the hospital. All of them had a PORT score of up to 70 points at first evaluation (Fine risk class of у3). A total of 683 (76%) of 896 assessable patients received ceftriaxone plus a macrolide. Eighty (12%) of 683 patients were excluded from the final analysis because ingestion difficulties (5 patients [0.7%]), previous receipt of antimicrobial therapy (18 patients [2.6%]), requirement of mechanical ventilation (10 patients [1.5%]), and death within the first 24 h of admission (4 patients [0.6%]). The remaining 42 patients (6.1%) were excluded because of they had received a macrolide other than clarithromycin or azithromycin. Six hundred three patients were studied (67% of the 896 evaluated); 220 (36.5%) of them received clarithromycin, and 383 (63.5%) received azithromycin (figure 1).
The proportion of patients in each PORT or Fine risk class was similar for both treatment groups ( Table 2 shows the comparison of LOS and mortality P ! .01 between treatment groups with regard to PORT severity categories. As mentioned above, LOS was calculated for those patients who required hospitalization (i.e., patients from PORT risk classes 3-5). For hospitalized patients who no longer needed ICU admission, therapy with azithromycin plus a ceftriaxone remained a significant predictor of good outcome (lower mortality and shorter LOS) after controlling for age, sex, and PORT risk class (table 3) .
There were 32 positive blood cultures (14.5%) among 220 patients receiving clarithromycin, and there were 41 positive blood cultures (10.7%) among 383 patients receiving azithro- 
mycin (
). The proportion of cases of bacteremia among P p .6 patients who died was significantly higher than in the global series ( ), but a similar distribution was observed be-P p .04 tween groups: 5 (36%) of 14 in the azithromycin group and 6 (38%) of 16 in the clarithromycin group ( ). Examination P p .7 of sputum samples had helped to establish the etiology for ∼65% of patients, but isolates with the usual colonizing flora were common in both groups (mean, 58.6%), even after culturing only suitable sputum stains [14] . Serological test results positive for any "atypical" agent or respiratory virus increased 4-fold for the basal determination in 56 cases (25%) from the clarithromycin group and in 115 cases (30%) from the azithromycin group ( ). Mixed etiologies, related to both pos-P p .6 itive serological test results and positive blood culture or respiratory sample findings, were found in 18% of cases. No statistically significant difference was found in etiology distribution, either pyogenic or atypical between groups (table 4) .
DISCUSSION
The present report shows a different outcome for mild CAP in aged patients when treatment with ceftriaxone is combined with a 3-day course of azithromycin and a 10-day course of clarithromycin. Both study groups had comparable severity scores and etiologic patterns.
Specialists will often include a macrolide in the treatment of mild and severe CAP [16, 17] . However, whether a macrolide is needed remains controversial [18, 19] . To assess the value of these antibiotics, it is important to know the likelihood of a bacterial-pyogenic versus atypical or mixed infection, but other aspects, such as the anti-inflammatory effect of macrolides, should be considered. Because an etiologic diagnosis of CAP in elderly patients is problematic, the choice for a particular antibiotic treatment is usually empirical. Effective management of CAP requires consideration of clinical and practical antibiotic dosing issues and patient compliance, the susceptibility and resistance of possible causative pathogens, and the pharmacokinetic basis for treatment with macrolide antibiotics. Several macrolide agents are available for the treatment of CAP. With the restrictions around infection and colonization status of an organism in mind, as well as the limitation of examination of sputum samples and serological testing, it could be observed that the isolated possible pathogens were susceptible to azithromycin and clarithromycin, with the expected exception of L. pneumophila isolates, which had a better in vitro susceptibility profile for azithromycin [20] . The low incidences of L. pneumophila and "invasive pathogens" (bacteremia) detected in both treatment groups make the clinical relevance of these findings questionable. However, the principal aim of the study was to investigate the outcome in terms of LOS and mortality in an inpatient population with CAP for which a small number of positive microbiologic results would usually be available.
An important bias of the present study is the decision of the attending physician to assign macrolide treatment. Few data are available regarding the usefulness of macrolides in combination with cephalosporins or other b-lactams [2, 3, 21] in aged people with CAP, and it is not clear why the proportion of patients with better outcomes receiving azithromycin was higher in the present study than in studies reported in the literature. The open-label design of the study makes selection bias possible. Doctors might be inclined to prescribe azithromycin to patients with apparently good status more often than to severely ill patients. The unexpected preliminary results regarding LOS and mortality between groups prompted us to review these findings. First, we checked the homogeneity and comparability of the 2 treatment arms (ceftriaxone-clarithromycin and ceftriaxone-azithromycin); we also assumed that we underestimated the severity variables at presentation or that we underestimated the presence of chronic underlying diseases; all patients were scored according to the PORT study group. When all patients were evaluated, a similar distribution of the severity scores was found in both treatment groups.
Because our study suggests that the outcome for patients with CAP who do not require ICU admission may depend on the macrolide associated with the cephalosporin, some evidence must be considered, as follows. First, the rate of mortality is significantly increased in aged patients with mild or severe CAP. Moreover, it may be caused by a number of different pathogens [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , unknown and indistinguishable at the time of presentation [16] , which make empirically combined therapy ad-visable. Patients with mixed pneumonia due to Streptococcus pneumoniae and Chlamydia pneumoniae in whom antimicrobial therapy was targeted only against S. pneumoniae experienced a significantly longer delay in recovering, compared with patients who received a macrolide additionally [32, 33] .
Second, it is possible that there exists an anti-inflammatory [34] effect above and beyond the antimicrobial profile of the drug that could affect the early outcome of CAP, could play a role in determining LOS, or could eventually cause death. Macrolides have been shown to affect a number of the processes involved in inflammation, including the migration of neutrophils, the oxidative burst in phagocytes, and the production of various cytokines, although the precise mechanisms are not clear. These effects have been linked to the ability of macrolides to accumulate in mammalian cells, and the literature describes abundant examples [35] [36] [37] [38] [39] [40] . Our observations cannot allow us to draw additional conclusions about the anti-inflammatory effect of azithromycin compared with clarithromycin because the study was not designed that way. Nevertheless, the favorable outcome observed in 383 patients treated with azithromycin in combination with ceftriaxone is encouraging enough to suppose it to be an excellent choice for treatment of patients with mild CAP.
Third, azithromycin penetrates the lower respiratory tract well [41] [42] [43] [44] . The pharmacokinetic characteristics [45, 46] of azithromycin result in less-frequent administration and shorter treatment courses, compared with erythromycin or clarithromycin-containing regimens, allowing for a shorter treatment [47] . Compliance is influenced not only by the duration of therapy but also by the relatively simple, once-daily dosing of azithromycin. A 3-day course of therapy includes the usual period of hospitalization for patients with CAP and assures adherence as well as completion of the full dose of azithromycin. Furthermore, adherence to a clarithromycin regimen, which is administered twice per day for almost 10 days, is presumed to vary, because patients with CAP are frequently discharged on the fifth day of hospitalization (median of 7 days of hospitalization in our series), so the patients finish the clarithromycin course as outpatients. In contrast, it is likely that the 3-day course of azithromycin will be completed; in our practice, discharge of patients before 72 h is exceptional (patients discharged from the emergency department were not included). This presumption does not invalidate our hypothesis that azithromycin is a better choice.
Fourth, the mean age of patients treated with azithromycin was surprisingly higher than the mean age of patients treated with clarithromycin (71.5 vs. 65.8 years;
). According to P ! .01 the published observations of Fine et al. [12] , in elderly people, age boosts the severity score, because it is supposed that aged patients are more likely to develop serious complications or multiorgan failure. The present study indirectly shows that, when no other severity criteria or comorbidities are implicated, the outcome for aged patients with mild CAP is favorable. Nevertheless, recovery is delayed among those patients, as the median LOS of 7 days illustrates.
The present study was not randomized or blinded, but its prospective study protocol provides an interesting approach to empirical strategies, the main advantage of which is its applicability to elderly patients with CAP [48, 49] . Even though this study was randomized, the PORT score evaluation illustrates that the distribution of severity between groups was balanced and comparable. Given that data from prospective, randomized trials are the major source of information for evidence-based treatment recommendations, we conclude that the results presented here should be used as a springboard for further studies, preferably randomized as well as complemented with the study of cytokines or additional proinflammatory-based determinations (C-reactive protein, pro-calcitonin, and interleukin). Such studies should assess with greater precision whether the use of different macrolides in elderly patients who are not severely ill could improve the outcome of CAP and decrease the exposure to-and cost of-antimicrobial therapies.
